相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Pan-cancer Analysis of Homologous Recombination Repair-associated Gene Alterations and Genome-wide Loss-of-Heterozygosity Score
C. Benedikt Westphalen et al.
CLINICAL CANCER RESEARCH (2022)
Phase II study of combination pembrolizumab and olaparib in patients with advanced cholangiocarcinoma: Interim results
Chao Yin et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
BLM helicase inhibition synergizes with PARP inhibition to improve the radiosensitivity of olaparib resistant non-small cell lung cancer cells by inhibiting homologous recombination repair
Yangyang Kong et al.
CANCER BIOLOGY & MEDICINE (2022)
Synergistic targeting and resistance to PARP inhibition in DNA damage repair-deficient pancreatic cancer
Johann Gout et al.
GUT (2021)
Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance
Dae-Seok Kim et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2021)
RAD51 paralog function in replicative DNA damage and tolerance
Hayley L. Rein et al.
CURRENT OPINION IN GENETICS & DEVELOPMENT (2021)
Advanced Prostate Cancer with ATM Loss: PARP and ATR Inhibitors
Antje Neeb et al.
EUROPEAN UROLOGY (2021)
Investigational PARP inhibitors for the treatment of biliary tract cancer: spotlight on preclinical and clinical studies
Rutika Mehta et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2021)
Promising Molecular Targets for the Targeted Therapy of Biliary Tract Cancers: An Overview
Wenwei Yang et al.
ONCOTARGETS AND THERAPY (2021)
Co-existing TP53 and ARID1A mutations promote aggressive endometrial tumorigenesis
Jake J. Reske et al.
PLOS GENETICS (2021)
Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial
Angela Lamarca et al.
LANCET ONCOLOGY (2021)
The Emerging Role of Immunotherapy in Intrahepatic Cholangiocarcinoma
Oraianthi Fiste et al.
VACCINES (2021)
Targeting ARID1A mutations in cancer
Jaren Mullen et al.
CANCER TREATMENT REVIEWS (2021)
Homologous Recombination Deficiency: Cancer Predispositions and Treatment Implications
MingRen Toh et al.
ONCOLOGIST (2021)
Loss of ATRX confers DNA repair defects and PARP inhibitor sensitivity
Jennifer Garbarino et al.
TRANSLATIONAL ONCOLOGY (2021)
Rucaparib in patients with BAP1-deficient or BRCA1-deficient mesothelioma (MiST1): an open-label, single-arm, phase 2a clinical trial
Dean A. Fennell et al.
LANCET RESPIRATORY MEDICINE (2021)
Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation The Phase 3 Randomized Clinical ClarIDHy Trial
Andrew X. Zhu et al.
JAMA ONCOLOGY (2021)
ARID1A Variations in Cholangiocarcinoma: Clinical Significances and Molecular Mechanisms
Shankun Zhao et al.
FRONTIERS IN ONCOLOGY (2021)
Clinical Efficacy of Olaparib in IDH1/IDH2-Mutant Mesenchymal Sarcomas
Joseph P. Eder et al.
JCO PRECISION ONCOLOGY (2021)
Synergism between ATM and PARP1 Inhibition Involves DNA Damage and Abrogating the G2 DNA Damage Checkpoint
Joyce P. Y. Mak et al.
MOLECULAR CANCER THERAPEUTICS (2020)
Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer
A. G. Waks et al.
ANNALS OF ONCOLOGY (2020)
Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study
Wassim Abida et al.
CLINICAL CANCER RESEARCH (2020)
Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial
Richard T. Penson et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Ovarian and Breast Cancer Risks Associated With Pathogenic Variants in RAD51C and RAD51D
Xin Yang et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2020)
ATM, ATR and DNA-PKcs kinases-the lessons from the mouse models: inhibition ≠ deletion
Demis Menolfi et al.
CELL AND BIOSCIENCE (2020)
Phase II basket trial of olaparib and durvalumab in patients (pts) with isocitrate dehydrogenase (IDH) mutated solid tumors.
Eric Xueyu Chen et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study
Ghassan K. Abou-Alfa et al.
LANCET ONCOLOGY (2020)
Current Understanding of RAD52 Functions: Fundamental and Therapeutic Insights
Vanesa Gottifredi et al.
CANCERS (2020)
Exploring the Synergy between PARP and CHK1 Inhibition in Matched BRCA2 Mutant and Corrected Cells
Hannah L. Smith et al.
CANCERS (2020)
DNA Mismatch Repair Gene Variants in Sporadic Solid Cancers
Fabian Caja et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Design, Synthesis, and Evaluation of New Quinazolinone Derivatives that Inhibit Bloom Syndrome Protein (BLM) Helicase, Trigger DNA Damage at the Telomere Region, and Synergize with PARP Inhibitors
Chen-Xi Wang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Overcoming PARP inhibitor resistance in ovarian cancer: what are the most promising strategies?
Daniel Martin Klotz et al.
ARCHIVES OF GYNECOLOGY AND OBSTETRICS (2020)
Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models
Hyoung Kim et al.
NATURE COMMUNICATIONS (2020)
TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes
Nadine M. Tung et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Case Report: BAP1 Mutation and RAD21 Amplification as Predictive Biomarkers to PARP Inhibitor in Metastatic Intrahepatic Cholangiocarcinoma
Francesco Sabbatino et al.
FRONTIERS IN ONCOLOGY (2020)
RAD50 deficiency is a predictor of platinum sensitivity in sporadic epithelial ovarian cancers
Adel Alblihy et al.
MOLECULAR BIOMEDICINE (2020)
Pan-Cancer Analysis of BRCA1 and BRCA2 Genomic Alterations and Their Association With Genomic Instability as Measured by Genome-Wide Loss of Heterozygosity
Ethan S. Sokol et al.
JCO PRECISION ONCOLOGY (2020)
Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial
Panagiotis A. Konstantinopoulos et al.
LANCET ONCOLOGY (2019)
Clinical presentation, diagnosis and staging of cholangiocarcinoma
Alejandro Forner et al.
LIVER INTERNATIONAL (2019)
Frequency of BRCA mutation in biliary tract cancer and its correlation with tumor mutational burden (TMB) and microsatellite instability (MSI).
Gilbert Spizzo et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Combined Tumor Sequencing and Case-Control Analyses of RAD51C in Breast Cancer
Na Li et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2019)
Loss of ARID1A in Tumor Cells Renders Selective Vulnerability to Combined Ionizing Radiation and PARP Inhibitor Therapy
Youngran Park et al.
CLINICAL CANCER RESEARCH (2019)
Poly(ADP-ribose) polymerase-1 antagonizes DNA resection at double-strand breaks
Marie-Christine Caron et al.
NATURE COMMUNICATIONS (2019)
PARP Inhibitors in Ovarian Cancer: The Route to Ithaca
Stergios Boussios et al.
DIAGNOSTICS (2019)
PARP Inhibition in Cancer: An Update on Clinical Development
Esha Sachdev et al.
TARGETED ONCOLOGY (2019)
PARP Inhibitor Resistance: A Tug-of-War in BRCA-Mutated Cells
Sylvie M. Noordermeer et al.
TRENDS IN CELL BIOLOGY (2019)
RAD52 as a Potential Target for Synthetic Lethality-Based Anticancer Therapies
Monika Toma et al.
CANCERS (2019)
COSMIC: the Catalogue Of Somatic Mutations In Cancer
John G. Tate et al.
NUCLEIC ACIDS RESEARCH (2019)
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer
I. Ray-Coquard et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Cholangiocarcinoma - evolving concepts and therapeutic strategies
Sumera Rizvi et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
ATM and ATR play complementary roles in the behavior of excitatory and inhibitory vesicle populations
Aifang Cheng et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer
C. Cruz et al.
ANNALS OF ONCOLOGY (2018)
ATRX Promotes DNA Repair Synthesis and Sister Chromatid Exchange during Homologous Recombination
Szilvia Juhasz et al.
MOLECULAR CELL (2018)
ARID1A loss in cancer: Towards a mechanistic understanding
Radhika Mathur
PHARMACOLOGY & THERAPEUTICS (2018)
Simultaneous Targeting of PARP1 and RAD52 Triggers Dual Synthetic Lethality in BRCA-Deficient Tumor Cells
Katherine Sullivan-Reed et al.
CELL REPORTS (2018)
The Tumor Suppressor ARID1A Controls Global Transcription via Pausing of RNA Polymerase II
Marco Trizzino et al.
CELL REPORTS (2018)
A Quantitative Chemotherapy Genetic Interaction Map Reveals Factors Associated with PARP Inhibitor Resistance
Hsien-Ming Hu et al.
CELL REPORTS (2018)
Mechanisms of PARP inhibitor sensitivity and resistance
Alan D. D'Andrea
DNA REPAIR (2018)
Werner Syndrome Protein and DNA Replication
Shibani Mukherjee et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Prevalence of Homologous Recombination-Related Gene Mutations Across Multiple Cancer Types
Arielle L. Heeke et al.
JCO PRECISION ONCOLOGY (2018)
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial
Elizabeth M. Swisher et al.
LANCET ONCOLOGY (2017)
Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial
Yung-Jue Bang et al.
LANCET ONCOLOGY (2017)
BAP1 regulates IP3R3-mediated Ca2+ flux to mitochondria suppressing cell transformation
Angela Bononi et al.
NATURE (2017)
2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity
Parker L. Sulkowski et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib
Chen Wang et al.
TRANSLATIONAL ONCOLOGY (2017)
Rad52 competes with Ku70/ Ku86 for binding to S-region DSB ends to modulate antibody class-switch DNA recombination
Hong Zan et al.
NATURE COMMUNICATIONS (2017)
Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma
Olga Kondrashova et al.
CANCER DISCOVERY (2017)
Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma
Apinya Jusakul et al.
CANCER DISCOVERY (2017)
Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles (vol 18, pg 2780, 2017)
Farshad Farshidfar et al.
CELL REPORTS (2017)
Arid1a Has Context-Dependent Oncogenic and Tumor Suppressor Functions in Liver Cancer
Xuxu Sun et al.
CANCER CELL (2017)
PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression
Shiping Jiao et al.
CLINICAL CANCER RESEARCH (2017)
Common Molecular Subtypes Among Asian Hepatocellular Carcinoma and Cholangiocarcinoma
Jittiporn Chaisaingmongkol et al.
CANCER CELL (2017)
Management and Outcomes of Patients with Recurrent Intrahepatic Cholangiocarcinoma Following Previous Curative-Intent Surgical Resection
Gaya Spolverato et al.
ANNALS OF SURGICAL ONCOLOGY (2016)
Survival after resection of perihilar cholangiocarcinoma-development and external validation of a prognostic nomogram (vol 26, pg 1930, 2015)
B. Groot Koerkamp et al.
ANNALS OF ONCOLOGY (2016)
Mutant IDH1 Downregulates ATM and Alters DNA Repair and Sensitivity to DNA Damage Independent of TET2
Satoshi Inoue et al.
CANCER CELL (2016)
Copy number deletion of RAD50 as predictive marker of BRCAness and PARP inhibitor response in BRCA wild type ovarian cancer
Min Zhang et al.
GYNECOLOGIC ONCOLOGY (2016)
WRN regulates pathway choice between classical and alternative non-homologous end joining
Raghavendra A. Shamanna et al.
Nature Communications (2016)
Platinum and PARP Inhibitor Resistance Due to Overexpression of MicroRNA-622 in BRCA1-Mutant Ovarian Cancer
Young Eun Choi et al.
CELL REPORTS (2016)
Expression of an Oncogenic BARD1 Splice Variant Impairs Homologous Recombination and Predicts Response to PARP-1 Inhibitor Therapy in Colon Cancer
Ozkan Ozden et al.
SCIENTIFIC REPORTS (2016)
The DNA Damage Response: Implications for Tumor Responses to Radiation and Chemotherapy
Michael Goldstein et al.
ANNUAL REVIEW OF MEDICINE, VOL 66 (2015)
Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer
Yung-Jue Bang et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer
Susan J. Ramus et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors
Jianfeng Shen et al.
CANCER DISCOVERY (2015)
Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer
Susan J. Ramus et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer
Tomoe Higuchi et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Therapeutic opportunities within the DNA damage response
Laurence H. Pearl et al.
NATURE REVIEWS CANCER (2015)
The Fanconi Anemia DNA Repair Pathway: Structural and Functional Insights into a Complex Disorder
Helen Walden et al.
ANNUAL REVIEW OF BIOPHYSICS, VOL 43 (2014)
Germline Mutations in BAP1 Impair Its Function in DNA Double-Strand Break Repair
Ismail Hassan Ismail et al.
CANCER RESEARCH (2014)
Dual Disruption of DNA Repair and Telomere Maintenance for the Treatment of Head and Neck Cancer
Shayanne A. Lajud et al.
CLINICAL CANCER RESEARCH (2014)
Rad51 supports triple negative breast cancer metastasis
Adrian P. Wiegmans et al.
ONCOTARGET (2014)
RAD51 overexpression is a negative prognostic marker for colorectal adenocarcinoma
Pierre Tennstedt et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
RAD51C-Deficient Cancer Cells Are Highly Sensitive to the PARP Inhibitor Olaparib
Ahrum Min et al.
MOLECULAR CANCER THERAPEUTICS (2013)
IDH1 and IDH2 Mutations in Tumorigenesis: Mechanistic Insights and Clinical Perspectives
Hui Yang et al.
CLINICAL CANCER RESEARCH (2012)
PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition
Yasir H. Ibrahim et al.
CANCER DISCOVERY (2012)
DNA repair dysregulation from cancer driver to therapeutic target
Nicola J. Curtin
NATURE REVIEWS CANCER (2012)
Secondary Somatic Mutations Restoring BRCA1/2 Predict Chemotherapy Resistance in Hereditary Ovarian Carcinomas
Barbara Norquist et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
RAD51 paralogs: Roles in DNA damage signalling, recombinational repair and tumorigenesis
Natsuko Suwaki et al.
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY (2011)
Markers of bile duct tumors
Giulia Malaguarnera et al.
WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY (2011)
A Marker of Homologous Recombination Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Primary Breast Cancer
Monika Graeser et al.
CLINICAL CANCER RESEARCH (2010)
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer.
Juan Valle et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Prognostic Factors and Predictive Model in Patients With Advanced Biliary Tract Adenocarcinoma Receiving First-Line Palliative Chemotherapy
Inkeun Park et al.
CANCER (2009)
Burden of Digestive Diseases in the United States Part III: Liver, Biliary Tract, and Pancreas
James E. Everhart et al.
GASTROENTEROLOGY (2009)
Intrahepatic cholangiocardnoma - Rising frequency, improved survival, and determinants of outcome after resection
Itaru Endo et al.
ANNALS OF SURGERY (2008)
Surgical resection of hilar cholangiocarcinoma: Analysis of survival and postoperative complications
Suguru Hasegawa et al.
WORLD JOURNAL OF SURGERY (2007)
Cholangiocarcinoma - Thirty-one-year experience with 564 patients at a single institution
Michelle L. DeOliveira et al.
ANNALS OF SURGERY (2007)
Hepatocellular carcinoma: Interventional bridging to liver transplantation
A Lubienski
TRANSPLANTATION (2005)
Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma - Implications for adjuvant therapeutic strategies
WR Jarnagin et al.
CANCER (2003)
The Rad52-Rad59 complex interacts with Rad51 and replication protein A
AP Davis et al.
DNA REPAIR (2003)
BARD1 induces BRCA1 intranuclear foci formation by increasing RING-dependent BRCA1 nuclear import and inhibiting BRCA1 nuclear export
M Fabbro et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
分享论文
